GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Asymchem Laboratories Tianjin Co Ltd (HKSE:06821) » Definitions » Valuation Rank

Asymchem Laboratories Tianjin Co (HKSE:06821) Valuation Rank


View and export this data going back to 2021. Start your Free Trial

What is Asymchem Laboratories Tianjin Co Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


Asymchem Laboratories Tianjin Co Valuation Rank Related Terms

Thank you for viewing the detailed overview of Asymchem Laboratories Tianjin Co's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Asymchem Laboratories Tianjin Co Business Description

Traded in Other Exchanges
Address
No. 6 Dongting Third Street, Economic and Technological Development Zone, Tianjin, CHN, 300457
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development manufacturing organization solutions throughout the drug development and manufacturing process. The Group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing which focuses on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
Executives
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Citigroup Inc. 2201 Interest of corporation controlled by you
Schroders Plc 2102 Investment manager
Norges Bank 2101 Beneficial owner
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Springhill Fund Asset Management (hk) Company Limited 2102 Investment manager
Springhill Fund Limited 2201 Interest of corporation controlled by you
Springhill Global Feeder Fund Limited 2201 Interest of corporation controlled by you
Springhill Master Fund Limited 2101 Beneficial owner
Morgan Stanley 2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd. 2102 Investment manager
Hhlr Fund, L.p. 2101 Beneficial owner
Jpmorgan Asset Management (asia Pacific) Limited 2102 Investment manager
Fidelity Management & Research Company Llc